Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Investigation into the cardiotoxic effects of doxorubicin on contractile function and the protection afforded by cyclosporin A using the work-loop assay.

Gharanei M, Hussain A, James RS, Janneh O, Maddock H.

Toxicol In Vitro. 2014 Aug;28(5):722-31. doi: 10.1016/j.tiv.2014.01.011. Epub 2014 Feb 7.

PMID:
24509045
2.

Doxorubicin induced myocardial injury is exacerbated following ischaemic stress via opening of the mitochondrial permeability transition pore.

Gharanei M, Hussain A, Janneh O, Maddock HL.

Toxicol Appl Pharmacol. 2013 Apr 15;268(2):149-56. doi: 10.1016/j.taap.2012.12.003. Epub 2012 Dec 20.

PMID:
23262186
3.

Morphine is protective against doxorubicin-induced cardiotoxicity in rat.

Kelishomi RB, Ejtemaeemehr S, Tavangar SM, Rahimian R, Mobarakeh JI, Dehpour AR.

Toxicology. 2008 Jan 14;243(1-2):96-104. Epub 2007 Sep 29.

PMID:
17988779
4.

Stabilization of mitochondrial membrane potential prevents doxorubicin-induced cardiotoxicity in isolated rat heart.

Montaigne D, Marechal X, Baccouch R, Modine T, Preau S, Zannis K, Marchetti P, Lancel S, Neviere R.

Toxicol Appl Pharmacol. 2010 May 1;244(3):300-7. doi: 10.1016/j.taap.2010.01.006. Epub 2010 Jan 20.

PMID:
20096298
5.

The modulatory effect of lithium on doxorubicin-induced cardiotoxicity in rat.

Rahimi Balaei M, Momeny M, Babaeikelishomi R, Ejtemaei Mehr S, Tavangar SM, Dehpour AR.

Eur J Pharmacol. 2010 Sep 1;641(2-3):193-8. doi: 10.1016/j.ejphar.2010.05.046. Epub 2010 Jun 9.

PMID:
20534381
6.

Mechanisms underlying the protective effect of eugenol in rats with acute doxorubicin cardiotoxicity.

Fouad AA, Yacoubi MT.

Arch Pharm Res. 2011 May;34(5):821-8. doi: 10.1007/s12272-011-0516-2. Epub 2011 Jun 9.

PMID:
21656368
7.

Doxorubicin induces cardiomyocyte dysfunction via a p38 MAP kinase-dependent oxidative stress mechanism.

Wold LE, Aberle NS 2nd, Ren J.

Cancer Detect Prev. 2005;29(3):294-9. Epub 2004 Nov 23.

PMID:
15936597
8.

General oxidative stress during doxorubicin-induced cardiotoxicity in rats: absence of cardioprotection and low antioxidant efficiency of alpha-lipoic acid.

Ghibu S, Delemasure S, Richard C, Guilland JC, Martin L, Gambert S, Rochette L, Vergely C.

Biochimie. 2012 Apr;94(4):932-9. doi: 10.1016/j.biochi.2011.02.015. Epub 2011 Mar 15.

PMID:
21396425
9.

Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress.

Li W, Xu B, Xu J, Wu XL.

Basic Clin Pharmacol Toxicol. 2009 Mar;104(3):192-7. doi: 10.1111/j.1742-7843.2008.00358.x. Epub 2009 Jan 8.

10.

Interaction between doxorubicin and mitomycin C on mortality and myocardial contractility in guinea pig.

Monti E, Bossa R, Galatulas I, Favalli L, Villani F, Piccinini F.

Tumori. 1983 Apr 30;69(2):113-6.

PMID:
6407163
11.

Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.

Pouna P, Bonoron-Adèle S, Gouverneur G, Tariosse L, Besse P, Robert J.

Cancer Chemother Pharmacol. 1995;35(3):257-61.

PMID:
7805186
12.

Amidization of doxorubicin alleviates doxorubicin-induced contractile dysfunction and reduced survival in murine cardiomyocytes.

Turdi S, Xu P, Li Q, Shen Y, Kerram P, Ren J.

Toxicol Lett. 2008 May 30;178(3):197-201. doi: 10.1016/j.toxlet.2008.03.010. Epub 2008 Mar 25.

13.

Mechanisms responsible for reduced cardiotoxicity of mitoxantrone compared to doxorubicin examined in isolated guinea-pig heart preparations.

Chugun A, Uchide T, Tsurimaki C, Nagasawa H, Sasaki T, Ueno S, Takagishi K, Hara Y, Temma K.

J Vet Med Sci. 2008 Mar;70(3):255-64.

14.

Protective effect of tetrandrine on doxorubicin-induced cardiotoxicity in rats.

Xu M, Sheng L, Zhu X, Zeng S, Chi D, Zhang GJ.

Tumori. 2010 May-Jun;96(3):460-4.

15.

Oxidative stress and myocardial gene alterations associated with Doxorubicin-induced cardiotoxicity in rats persist for 2 months after treatment cessation.

Richard C, Ghibu S, Delemasure-Chalumeau S, Guilland JC, Des Rosiers C, Zeller M, Cottin Y, Rochette L, Vergely C.

J Pharmacol Exp Ther. 2011 Dec;339(3):807-14. doi: 10.1124/jpet.111.185892. Epub 2011 Sep 20.

16.

Effect of doxorubicin on postrest contraction in isolated rat hearts.

Asayama J, Tanaka T, Tatsumi T, Nakagawa C, Kobara M, Matoba S, Ohta B, Inoue D, Nakagawa M.

J Cardiovasc Pharmacol. 1995 Nov;26(5):693-7.

PMID:
8637182
17.
18.

Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro.

Xiao J, Sun GB, Sun B, Wu Y, He L, Wang X, Chen RC, Cao L, Ren XY, Sun XB.

Toxicology. 2012 Feb 6;292(1):53-62. doi: 10.1016/j.tox.2011.11.018. Epub 2011 Dec 6.

PMID:
22155320
19.

FGF-2 and FGF-16 protect isolated perfused mouse hearts from acute doxorubicin-induced contractile dysfunction.

Sontag DP, Wang J, Kardami E, Cattini PA.

Cardiovasc Toxicol. 2013 Sep;13(3):244-53. doi: 10.1007/s12012-013-9203-5.

PMID:
23430353
20.

Differing effects of inotropic agents on length change deactivation of isolated rat myocardium.

Leach JK, Ford LE, Perea JM, Grimes LA, Skipper BJ.

J Investig Med. 2002 Jan;50(1):61-6.

PMID:
11813830
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk